* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biofil Chemicals & Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofil Chemicals & Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofil Chemicals & Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Biofil Chemicals & Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofil Chemicals & Pharmaceuticals (BOM:524396) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. According to the industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #615 out of 956 companies in the Drug Manufacturers industry, placing it in the top 64.3%.
Is Biofil Chemicals & Pharmaceuticals' FCF Margin % too high?
Biofil Chemicals & Pharmaceuticals' current FCF Margin % is 0.00%. Based on the distribution chart, Biofil Chemicals & Pharmaceuticals ranks #615 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biofil Chemicals & Pharmaceuticals has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biofil Chemicals & Pharmaceuticals' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofil Chemicals & Pharmaceuticals ranks #615 out of 956 companies for FCF Margin %. This places Biofil Chemicals & Pharmaceuticals in the lower half of its industry. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biofil Chemicals & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofil Chemicals & Pharmaceuticals's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofil Chemicals & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals (BOM:524396) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹41.83, compared to a current price of ₹35.11 — trading 16.1% below its estimated fair value. The current FCF Margin % is 0.00%. Biofil Chemicals & Pharmaceuticals' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biofil Chemicals & Pharmaceuticals (BOM:524396), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofil Chemicals & Pharmaceuticals (BOM:524396) Overvalued in 2026?
Based on GuruFocus' analysis, Biofil Chemicals & Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹35.11 is trading 16.1% below its estimated GF Value™ of ₹41.83.
GuruFocus considers Biofil Chemicals & Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:524396:
FCF Margin %: 0.00%
GF Value™: ₹41.83 vs. price of ₹35.11 (16.1% below fair value)
No single metric tells the full story. See the BOM:524396 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofil Chemicals & Pharmaceuticals Business Description
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company. It deals in the manufacturing and trading of pharmaceuticals. Further, the company also deals in providing job work facilities with respect to the manufacturing of pharmaceutical drugs. Its product portfolio comprises basic drugs and pharmaceuticals such as sodium citrate, sodium chloride, ferrous sulphate, micro crystalline cellulose, dicyclomine hydrochloride, and others. The company's operating segments are: Pharma, which derives maximum revenue, and Chemicals. Geographically, it caters to both domestic and international markets.
69GF Score
Get the complete analysis for BOM:524396
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524396 has been successfully added to your 
